Document is current
Any future updates will be listed below
-
Authors
Lee, Yu-Chen
Lin, Song-Chang
Yu, Guoyu
Zhu, Ming
Song, Jian H.
Rivera, Keith
Pappin, Darryl J.
Logothetis, Christopher J.
Panaretakis, Theocharis
Wang, Guocan https://orcid.org/0000-0002-8922-7249
Yu-Lee, Li-Yuan https://orcid.org/0000-0002-2353-406X
Lin, Sue-Hwa https://orcid.org/0000-0002-6122-4054
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA16672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1CA174798)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA16672)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA174798)
Cancer Prevention and Research Institute of Texas (RP150179)
Cancer Prevention and Research Institute of Texas (RP190252)
Cancer Prevention and Research Institute of Texas (RP150179)
Cancer Prevention and Research Institute of Texas (RP190252)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Prevention Research Institute of Texas
DH | NIHR | Public Health Research Programme (5P50CA140388)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 6 July 2021
Revised: 11 November 2021
Accepted: 19 November 2021
First Online: 29 November 2021
Competing interests
: CJL reports receiving commercial research grants from Janssen, ORIC Pharmaceuticals, Novartis, Aragon Pharmaceuticals, and honoraria from Merck, Sharp & Dohme, Bayer, Amgen. The other authors declare no competing interests.
